bisbenzimidazole has been researched along with sincalide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, B; Li, CQ; Luo, G; Zhang, CZ; Zhou, Y | 1 |
| Chen, J; Chen, Y; Gao, H; Hu, S; Li, Y; Tian, J; Zhang, X | 1 |
2 other study(ies) available for bisbenzimidazole and sincalide
| Article | Year |
|---|---|
Collagen II/hyaluronan/chondroitin-6-sulfate tri-copolymer scaffold for nucleus pulposus tissue engineering.
Topics: Animals; Biocompatible Materials; Bisbenzimidazole; Cell Proliferation; Cell Survival; Chondroitin Sulfates; Collagen Type II; Coloring Agents; DNA; Extracellular Matrix; Gene Expression; Hyaluronic Acid; Immunohistochemistry; Methylene Blue; Microscopy, Electron, Scanning; Rabbits; Reverse Transcriptase Polymerase Chain Reaction; Sincalide; Tissue Scaffolds | 2010 |
Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
Topics: Bisbenzimidazole; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Humans; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptors, Estrogen; Signal Transduction; Sincalide; Triple Negative Breast Neoplasms | 2023 |